Phase II study of capecitabine and temozolomide (CAPTEM)in patients with unresectable neuroendocrien tumor - CAPTEM therapy for unresectable neuroendocrine tumor

yokohama city university hospital oncology division0 sites35 target enrollmentSeptember 17, 2016

Conditionsgastroenteropancreatic neuroendocrine tumor

Overview

Phase: 未知
Intervention: Not specified
Conditions: gastroenteropancreatic neuroendocrine tumor
Sponsor: yokohama city university hospital oncology division
Enrollment: 35
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

undisclosed

Registry

who.int

Start Date

September 17, 2016

End Date

July 31, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

yokohama city university hospital oncology division

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Hb \< 8\.0g/dl WBC \<3000 Neutrocyte \<1500 Plt \<100000 severe liver or renal disease T\-bil\> 3ULN Alb \<3\.0g/dl AST\> 5 X ULN ALT\> 5 X ULN brain metastasis severe bone metastasis uncontrolable DM severe heart disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Phase 1

Medical treatment of patients with cancer in colon or rectumPatients with refractory colorectal cancerMedDRA version: 16.1Level: HLTClassification code 10010023Term: Colorectal neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2012-002327-15-DKOdense University Hospital80

Completed

Phase 2

Capecitabine and Temozolomide for Neuroendocrine CancersNeuroendocrine Tumors

NCT00869050Columbia University41

Completed

Phase 2

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsGastrinomaGlucagonomaInsulinomaPancreatic Polypeptide TumorRecurrent Islet Cell CarcinomaRecurrent Pancreatic CancerSomatostatinomaStage III Pancreatic CancerStage IV Pancreatic Cancer

NCT01525082Shaheen Shagufta20

Active, not recruiting

Phase 2

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine TumorsGastrinomaGlucagonomaInsulinomaIslet Cell CarcinomaPancreatic Polypeptide TumorRecurrent Islet Cell CarcinomaSomatostatinoma

NCT01824875ECOG-ACRIN Cancer Research Group144

Terminated

Phase 2

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary AdenomasRecurrent Pituitary Adenomas

NCT03930771Weill Medical College of Cornell University1